Case study of a patient who participated in Ixaka’s REX-001 clinical trial 01/12/2020 Case study of a patient who participated in Ixaka’s REX-001 clinical trial
Ixaka Appoints Karen Miller as Chief Scientific Officer 12/07/2022 London, UK, 12 July 2022: Ixaka Ltd, an integrated cell and gene therapy company focused on boosting the natural power… Read More
Ixaka and Minaris Regenerative Medicine Sign Tech Transfer and GMP Manufacturing Agreement for Lead Cell Therapy Candidate REX-001 27/06/2022 REX-001 is an autologous multi-cell therapy (MCT) in development for the treatment of chronic limb-threatening ischemia (CLTI) in patients with… Read More
Ixaka expands IP portfolio to enable use of targeted nanoparticle in vivo gene delivery technology with any cargo in any therapeutic area 21/03/2022 London, UK, 21 March 2022– Ixaka Ltd, an integrated cell and gene therapy company, today announces an expansion of its… Read More